Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy

Figures

• 

  Figure 1. Collagen Biomarker Levels During Follow-Up Levels of (A) log PRO-C3, (B) log C3M, (C) log CTX-III, (D) log endotrophin, (E) log PRO-C6, and (F) log C6M, from baseline to 52 weeks in patients randomized to pirfenidone and placebo. Values are mean ± 95% CIs. ∗P < 0.05.

• 

  Figure 2. Univariable Associations Between Change in Extracellular Volume and Collagen Biomarkers Univariable associations between change in ECV and change in (A) log PRO-C3, (B) log C3M, (C) log CTX-III, (D) log endotrophin, (E) log PRO-C6, and (F) log C6M from baseline to week 52. Regression line (blue) and 95% CI (gray). ECV = extracellular volume.

• 

  Figure 3. Univariable Associations Between Baseline Extracellular Volume and Collagen Biomarkers Univariable associations between baseline ECV and baseline (A) log PRO-C3, (B) log C3M, (C) log CTX-III, (D) log endotrophin, (E) log PRO-C6, and (F) log C6M. Regression line (blue) and 95% CI (gray). Abbreviation as in Figure 2.

• 

  Central Illustration. Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy ECV = extracellular volume; HFpEF = heart failure with preserved ejection fraction.